Turning Point Therapeutics Inc

+0.11 (+0.15%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)3.73B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.78 Million
Adjusted EPS-$1.70
See more estimates
10-Day MA$75.04
50-Day MA$70.88
200-Day MA$44.64
See more pivots

Turning Point Therapeutics Inc Stock, NASDAQ:TPTX

10628 Science Center Drive, Suite 200, San Diego, California 92121
United States of America
Phone: +1.858.926.5251
Number of Employees: 250


Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.